Re: Predictability of adjuvant trastuzumab benefit in N9831 patients using the ASCO/CAP HER2-positivity criteria

Antonio C. Wolff, M. Elizabeth Hammond, Daniel F. Hayes

Research output: Contribution to journal › Letter › peer-review

14 Scopus citations

Fingerprint

Dive into the research topics of 'Re: Predictability of adjuvant trastuzumab benefit in N9831 patients using the ASCO/CAP HER2-positivity criteria'. Together they form a unique fingerprint.